cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
October 20.2026
3 Minutes Read

Helius Therapeutics and University of Auckland Launch Phase 2 Cannabis Sleep Trial

Minimalistic illustration of a tug-of-war on cliffs with green backdrop.

Helius Therapeutics Enters Groundbreaking Cannabis Sleep Study

Helius Therapeutics, a trailblazer in New Zealand's medicinal cannabis sector, is embarking on an exciting journey to explore the potential of cannabis as a sleep aid. The company has signed a pivotal supply agreement with the University of Auckland for a Phase 2 clinical trial, which aims to investigate the effectiveness of cannabis-derived medicine for patients struggling with chronic back pain and sleep disturbances.

Understanding the CPS Trial's Importance

Known as the CPS Trial (Cannabis, Pain, Sleep), this innovative study will unfold over seven months, with participation from prominent institutions including Tauranga Hospital and the University of Otago. Lead investigator Dr. Saad Anis, an experienced pain medicine physician, emphasized the urgent need for credible research, noting that over 20% of New Zealand adults endure chronic non-cancer pain, often accompanied by sleep issues. "Many patients express interest in cannabis-derived medicines, yet definitive evidence is scarce, making it a challenge for healthcare providers to recommend them with confidence," he remarked.

The Mechanics of the Trial

Participants will engage in a randomized, double-blind, placebo-controlled crossover study, taking the study medicine at bedtime for three months, followed by a placebo for an additional three months. To track the participants’ sleep quality, their sleep patterns will be monitored meticulously using wrist-worn devices. The primary outcome is assessed through the Insomnia Severity Index, complemented by measures of sleep patterns derived from actigraphy.

The Significance of High-Quality Evidence

The trial, supported by the University of Auckland and an Australian and New Zealand College of Anaesthetists novice investigator grant, aims to produce important data that could reshape the landscape of medicinal cannabis. "This independent study is a crucial step forward for the sector, potentially improving general practice prescriptions and enhancing trust in cannabis therapies," noted Helius Therapeutics CEO Zoë Reece. As the medicinal cannabis sector evolves, effective clinical trials like CPS are viewed as building blocks towards validating these therapies.

Growing Demand and Future Prospects

As per Health New Zealand's data, medicinal cannabis dispensings have skyrocketed from 4,875 in 2020 to an impressive 389,668 in 2025. This surge highlights the increasing demand for medicinal cannabis as awareness and acceptance grow. Helius Therapeutics is keenly aware of this potential, demonstrating dedication to ensuring reliable and high-quality cannabis products. With over 80 products meeting the rigorous standards of New Zealand's Medicinal Cannabis Scheme, the outlook remains buoyant.

What’s Next for the CPS Trial?

The results of this pioneering CPS Trial are expected to be published in early 2028, with anticipation high amongst both the medical community and patients alike. Continued research will not only empower practitioners with data but also open avenues for patients to access cannabis therapies that genuinely improve their quality of life.

Join the Conversation

As the debate around medicinal cannabis evolves, it is crucial for industry stakeholders and patients to stay informed and engaged. Trials like the CPS could redefine how cannabis is perceived and utilized in healthcare, leading to more informed decisions in medical practices. Let's keep sharing these impactful developments!

Brands

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

The Race for Affordable Medical Cannabis: UK vs Germany Pricing Trends

Update The Cannabis Market Race: UK vs Germany As the European medical cannabis landscape continues to evolve, UK and Germany stand as the two major players, each contributing to a diverse market for patients. Recent changes in pricing dynamics have stirred interest and led to shifts in purchasing behaviors, particularly for patients seeking affordable cannabis alternatives. This comparison highlights the developing landscape of both countries and points towards the implications of these trends for executive cannabis professionals. Price Trends Shifting Dramatically Previously characterized by high prices, Germany has witnessed a notable price decline for cannabis flower. As of April 2026, the average price dropped to €6.55 per gram, a striking decrease from nearly €10 per gram just a year prior. Such a change has largely been attributed to an influx of products flooding the market, enhancing competition among licensed producers and imports. In contrast, the UK has shown a much more stable pricing trend, with average flower prices set at €7.78 per gram. This divergence speaks volumes about the market maturation process in both countries. As the UK market remains mostly private, its smaller number of flower SKUs, at 683 compared to Germany’s 1,748, could be a critical factor fueling a moderately steady price range. Market Expansion and Product Diversity The expansion of the medical cannabis market in both regions points to a future filled with potential and opportunity. Germany’s explosion of products—over 1,748 flower SKUs—is a clear indicator of a rapidly developing sector, bringing accessibility to thousands of patients previously left in the dark. In 2026, as more patients opt to pay privately due to regulatory changes, the numbers supporting this growth speak volumes. Conversely, the UK’s product variety increased significantly, growing 2.4 times compared to last year. This burgeoning market indicates a consumer base eager for more options, and the challenge now lies with clinic operators to ensure product quality and consistency. Regulatory Changes Impacting Patients Importantly, the impending BStabG regulation which removed medical cannabis flower from reimbursement under statutory health insurance (GKV) in Germany symbolizes a critical juncture for patient care. Although the overall price per gram has not yet reacted to these changes, the shift could lead to a significant increase in privately paying patients, currently estimated at around 65,000. How this regulation evolves will likely redefine patient accessibility and market flow. What Lies Ahead for Executives in Cannabis For executive cannabis professionals, this comparison calls for reflection on market strategy and adjustment. A deep understanding of the trends softening flower prices in Germany and the steady nature of the UK market is crucial for harnessing future opportunities. By recognizing the drive behind these shifts, executives can strategically position their businesses, focusing on product development, competitive pricing, and adapting to tailored patient needs. Engage with your peers in these discussions and remain informed about ongoing regulatory changes, as they will play a pivotal role in shaping the medical cannabis landscape of tomorrow.

The Science and Debate Behind Irradiated Medical Cannabis Explained

Update Understanding the Impact of Irradiated Medical Cannabis As the cannabis industry evolves, the conversation surrounding irradiated medical cannabis grows in complexity. This process, which utilizes ionizing radiation to reduce microbial loads in cannabis flower, raises significant questions regarding the safety and efficacy of the final product. While irradiation can dramatically lower levels of viable microorganisms, experts caution that it does not equate to sterilization. Following irradiation, some microorganisms, such as fungal spores and mycotoxins, may remain in the flower—prompting a need for rigorous testing and quality assurance in the industry. The Science Behind Irradiation Irradiation employs methods like gamma treatment, electron-beam treatment, and X-ray treatment, all of which target the DNA of the microorganisms, preventing their reproduction. For instance, studies have shown that electron-beam treatment can reduce viable fungal counts by a staggering 99.999%. However, this remarkable reduction does not make cannabis flower sterile, as viable counts alone don't account for other residual material, including allergenic fungal components. The science behind these treatments isn't just about the numbers; it emphasizes the importance of a comprehensive understanding of microbial quality and safety. Why Microbial Standards Matter in Cannabis Quality Control The regulatory landscape for cannabis varies significantly across regions. For example, imported medical cannabis may have different microbial standards compared to domestically grown products. In the UK, for instance, Health Canada allows higher yeast and mold counts for cannabis than what the UK's Medicines and Healthcare products Regulatory Agency (MHRA) permits for inhalation products. Understanding these differences is crucial for ensuring that patients receive high-quality medicine, free from harmful contaminants while maintaining efficacy. Counterarguments: The Case for Non-Irradiated Methods As an executive in the cannabis domain, one may wonder if irradiation is necessary in an era where preventative horticultural practices are becoming the gold standard in cultivation. At Glass Pharms, for example, robust hygiene practices, strict regulatory compliance, and controlled drying conditions are prioritized to minimize contamination risk without resorting to irradiation. This perspective aligns with a growing sentiment in the industry that preventive measures can often suffice, reducing dependency on treatments like irradiation. Future Trends in Medical Cannabis Irradiation Looking ahead, the discourse surrounding irradiation could pivot towards ongoing innovations in cultivation and testing techniques. As the market matures, the focus may shift to developing even more refined testing protocols that can encompass both viable and non-viable organisms and their potential impacts. This shift could lead to improvement in patient outcomes and systemic trust in the medicinal properties of cannabis products. Conclusion: The Path Forward for Cannabis Professionals For those involved in the cannabis industry, it's clear that navigating the debate around irradiated medical cannabis requires a multifaceted approach. Balancing the benefits of irradiation against the imperatives of preventive cultivation will be key driving forces in the evolution of the sector. Engaging in ongoing research and fostering transparent dialogue about quality standards will be essential. Stay informed and advocate for rigorous testing and quality control to ensure that all patients receive safe and effective cannabis.

Curaleaf's Compelling Bid vs. Organigram's Emerging Challenge: What's Next for Aurora?

Update A Shifting Landscape in Cannabis: Curaleaf vs. Aurora The cannabis industry is undergoing a significant transformation as Curaleaf Holdings pushes its acquisition bid for Aurora Cannabis, marking a crucial chapter in the race for market dominance. Over the past week, Curaleaf has ramped up its offer, increasing the bid by 25% to reach an implied price of $5.00 per share. This new strategy has altered the dynamics of the proposed merger, as Aurora’s position grows stronger due to a successful expansion of its production capabilities and rumors of competing bids from other cannabis giants. The Impact of Competitive Mergers and Acquisitions As Aurora prepares to double its annual flower production with the completion of a new EU-GMP facility in Germany, it stands on firmer ground than just days ago. Curaleaf’s latest offer, which includes a mix of shares and cash, now reflects an 86% premium over Aurora's previous market performance. Adding another dimension, media reports indicate that Organigram, backed by British American Tobacco, is also vying for a partnership with Aurora. This reflects a growing trend in the cannabis landscape where larger, established entities are eager to stake their claim in an increasingly lucrative market. Conflict and Criticism Amid Negotiations Curaleaf’s CEO, Boris Jordan, has not shied away from expressing his frustrations regarding Aurora’s management. Despite the dual pressures from shareholder sentiment and competitive bidding, Aurora remains steadfast, as indicated by CEO Miguel Martin’s comments treating Curaleaf's revised bid as merely procedural. This back-and-forth highlights the tumultuous nature of corporate negotiations in the cannabis sector, where reputations and future earnings are constantly at stake. A Broader Financial Landscape and Future Predictions The cannabis industry is vibrant but complex, with Curaleaf asserting that the merged entity would operate in 17 countries, boasting more than $1.5 billion in revenue. Should this merger materialize, industry experts predict it could streamline operations and foster innovation, but it will certainly stir conversations about market monopolization and corporate ethics. Looking ahead, industry analysts suggest that companies need to navigate not only financial implications but also the diverse regulations governing cannabis globally. What This Means for the Cannabis Community For professionals engaging in the cannabis sector, understanding these dynamics is key. The battle over Aurora reflects an industry maturity, with increased scrutiny from investors and regulators alike. The shifts and negotiations around this acquisition can impact everything from investment opportunities to public perceptions of corporate responsibility in cannabis. The ongoing developments encourage industry professionals to remain informed and adaptive, as these corporate decisions ripple through the market, influencing everything from local dispensaries to global cannabis strategies. The stark competition between Curaleaf and potential bidders, including Organigram, underscores a compelling narrative in the cannabis world, one that is still unfolding.

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*